Free Trial
NASDAQ:CAPS

Capstone (CAPS) Stock Price, News & Analysis

Capstone logo
$1.95 +0.04 (+2.09%)
As of 11:51 AM Eastern

About Capstone Stock (NASDAQ:CAPS)

Key Stats

Today's Range
$1.93
$2.00
50-Day Range
$1.66
$2.90
52-Week Range
$1.58
$16.18
Volume
19,832 shs
Average Volume
708,918 shs
Market Capitalization
$308,100.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

Receive CAPS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Capstone and its competitors with MarketBeat's FREE daily newsletter.

CAPS Stock News Headlines

Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new blockchain development…
See More Headlines

CAPS Stock Analysis - Frequently Asked Questions

Capstone's stock was trading at $2.40 at the beginning of the year. Since then, CAPS shares have decreased by 16.7% and is now trading at $2.00.
View the best growth stocks for 2025 here
.

Capstone (CAPS) raised $5 million in an IPO on Thursday, March 6th 2025. The company issued 1,250,000 shares at $4.00 per share.

Capstone's quiet period expired on Tuesday, April 15th. Capstone had issued 1,250,000 shares in its initial public offering on March 6th. The total size of the offering was $5,000,000 based on an initial share price of $4.00. During Capstone's quiet period, underwriters and any insiders involved in the IPO were restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Shares of CAPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CAPS
Web
N/A
Fax
N/A
Employees
38
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$43.42 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$301,780.00
Optionable
N/A
Beta
-0.82
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:CAPS) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners